Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today
announced that the U.S. Food and Drug Administration (FDA) has
approved Dupixent® (dupilumab) as an add-on maintenance treatment
of adults with inadequately controlled chronic obstructive
pulmonary disease (COPD) and an eosinophilic phenotype. Dupixent is
the first biologic medicine approved in the U.S. to treat these
patients.
“People living with inadequately controlled COPD have long
awaited new medicines to help manage the daily suffering they
experience from breathlessness, coughing, wheezing, exhaustion and
unpredictable hospitalization. These patients often struggle with
everyday activities many people take for granted such as taking a
walk or running errands outside the home,” said Jean Wright, M.D.,
Chief Executive Officer at The COPD Foundation. “We welcome the
approval of this new therapeutic option to offer patients a new way
to help gain better control of their disease.”
“This latest FDA approval for Dupixent represents new hope for
the hundreds of thousands of COPD patients in the U.S. who can
sometimes struggle just to breathe during their everyday lives,”
said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President
and Chief Scientific Officer at Regeneron, and a principal inventor
of Dupixent. “Dupixent has a proven track record as a
first-in-class medicine, providing benefit to the many patients
suffering from type 2 inflammatory related diseases such as asthma
and atopic dermatitis. This latest approval represents an important
next chapter for Dupixent, giving those with COPD a novel option
that has demonstrated the unprecedented ability to help patients
experience fewer exacerbations, while also helping them breathe
better and improve quality of life in Phase 3 trials.”
The FDA approval is based on data from two landmark pivotal
Phase 3 trials (BOREAS and NOTUS) that evaluated the efficacy and
safety of Dupixent compared to placebo in adults currently on
maximal standard-of-care inhaled therapy (nearly all on triple
therapy) with inadequately controlled COPD and blood eosinophils
≥300 cells per μL. Patients who received Dupixent in BOREAS (n=468)
and NOTUS (n=470) experienced the following outcomes, respectively,
compared to placebo (BOREAS n=471; NOTUS n=465):
- 30% and 34% reduction in the annualized rate of moderate or
severe COPD exacerbations over 52 weeks, the primary endpoint.
- 74mL and 68mL numerically greater improvements in
post-bronchodilator FEV1 from baseline at week 12 compared to
placebo, sustained at 52 weeks. Statistically significant
improvements of similar magnitude were observed in
pre-bronchodilator FEV1 from baseline at 12 and 52 weeks, a key
secondary endpoint.
- 51% response in a health-related quality of life measure in
both trials compared to 43% and 47% with placebo at 52 weeks, as
assessed by a 4-point improvement on the St. George’s Respiratory
Questionnaire (SGRQ).
Safety results in both trials were generally consistent with the
known safety profile of Dupixent in its approved indications. In
pooled BOREAS and NOTUS data, the most common adverse events (≥2%)
more frequently observed in patients on Dupixent compared to
placebo were viral infection, headache, nasopharyngitis, back pain,
diarrhea, arthralgia, urinary tract infection, local administration
reaction, rhinitis, eosinophilia, toothache and gastritis. While
less common, cholecystitis was reported in 0.6% of patients on
Dupixent compared to 0.1% of patients on placebo.
“Dupixent has already shown it can revolutionize the
treatment paradigm of many diseases driven in part by type 2
inflammation with high unmet medical needs, with one million
patients being treated globally across all currently approved
indications,” said Paul Hudson, Chief Executive Officer at Sanofi.
“With today’s approval, Dupixent once again paves the way and
becomes the first and only approved add-on biologic medicine for
inadequately controlled COPD, giving patients living with this
devastating disease the chance to look forward to the potential of
improved breathing and a life with fewer exacerbations.”
The FDA evaluated Dupixent under Priority Review, which is
reserved for medicines that represent potentially significant
improvements in efficacy or safety in treating serious conditions.
In July 2024, Regeneron and Sanofi announced the European
Commission approved Dupixent as an add-on maintenance treatment for
adults with uncontrolled COPD characterized by raised blood
eosinophils. Submissions are currently under review with other
regulatory authorities around the world, including in Japan.
About COPDCOPD is a respiratory disease that
damages the lungs and causes progressive lung function decline and
is the fourth leading cause of death worldwide. Symptoms include
persistent cough, excessive mucus production and shortness of
breath that may impair the ability to perform routine daily
activities, which may lead to sleep disturbances, anxiety and
depression. COPD is also associated with a significant health and
economic burden due to recurrent acute exacerbations that require
systemic corticosteroid medicine and/or antibiotics. Smoking and
exposure to noxious particles are key risk factors for COPD, but
even individuals who quit smoking can still have progressive lung
disease.
About half of COPD patients continue to experience exacerbations
despite being on triple inhaled therapy. In the U.S., approximately
300,000 people live with inadequately controlled COPD and an
eosinophilic phenotype. Patients with an eosinophilic phenotype
contribute to a ~30% increase in exacerbations and an increased
risk of COPD-related re-hospitalizations within a year.
About the Dupixent COPD Phase 3 Trial
ProgramBOREAS and NOTUS were replicate, randomized, Phase
3, double-blind, placebo-controlled trials that evaluated the
efficacy and safety of Dupixent in adults who were current or
former smokers with moderate-to-severe COPD with an eosinophilic
phenotype, as defined by blood eosinophils ≥300 cells per µL. The
trials included adults with COPD across a broad range of clinical
presentations, including those with chronic bronchitis and
emphysema. The trials enrolled 1,874 patients who were aged 40
to 80 years in BOREAS and 40 to 85 years in NOTUS.
During the 52-week treatment period, patients in BOREAS and
NOTUS received Dupixent or placebo every two weeks added to a
maximal standard-of-care inhaled triple therapy of ICS, LABA and
LAMA. Double maintenance therapy, which included LABA and LAMA, was
allowed if ICS was not appropriate.
The primary endpoint for BOREAS and NOTUS evaluated the
annualized rate of acute moderate or severe COPD exacerbations. Key
secondary endpoints included change from baseline in lung function
(assessed by pre-bronchodilator forced expiratory volume [FEV1]) at
12 and 52 weeks, change from baseline at 52 weeks in SGRQ total
score compared to placebo, and safety.
The results of both BOREAS and NOTUS were separately published
in The New England Journal of Medicine.
About Regeneron and Sanofi’s COPD Clinical Research
ProgramRegeneron and Sanofi are motivated to transform the
treatment paradigm of COPD by examining the role different types of
inflammation play in the disease progression through Dupixent, a
first-in-class biologic, and the investigation of itepekimab.
Dupixent inhibits the signaling of the interleukin-4 (IL-4) and
interleukin-13 (IL-13) pathways and the program focuses on a
specific population of people with evidence of type 2 inflammation.
Itepekimab is a fully human monoclonal antibody that binds to and
inhibits interleukin-33 (IL-33), an initiator and amplifier of
broad inflammation in COPD.
Itepekimab is currently under clinical investigation for COPD in
two Phase 3 trials and its safety and efficacy have not been
evaluated by any regulatory authority.
About DupixentDupixent, which was invented
using Regeneron’s proprietary VelocImmune® technology, is a fully
human monoclonal antibody that inhibits the signaling of the IL-4
and IL-13 pathways and is not an immunosuppressant. The Dupixent
development program has shown significant clinical benefit and a
decrease in type 2 inflammation in Phase 3 trials, establishing
that IL-4 and IL-13 are two of the key and central drivers of type
2 inflammation that play a major role in multiple related and often
co-morbid diseases.
Regeneron and Sanofi are committed to helping patients in the
U.S. who are prescribed Dupixent gain access to the medicine and
receive the support they may need with the DUPIXENT MyWay® program.
For more information, please call 1-844-DUPIXENT (1-844-387-4936)
or visit www.DUPIXENT.com.
Dupixent has received regulatory approvals in more than 60
countries in one or more indications including certain patients
with atopic dermatitis, asthma, chronic rhinosinusitis with nasal
polyps, eosinophilic esophagitis, prurigo nodularis, chronic
spontaneous urticaria, and COPD in different age populations. More
than 1,000,000 patients are being treated with Dupixent
globally.
About Regeneron's VelocImmune
TechnologyRegeneron's VelocImmune technology
utilizes a proprietary genetically engineered mouse platform
endowed with a genetically humanized immune system to produce
optimized fully human antibodies. When Regeneron's co-Founder,
President and Chief Scientific Officer George D. Yancopoulos was a
graduate student with his mentor Frederick W. Alt in 1985, they
were the first to envision making such a genetically humanized
mouse, and Regeneron has spent decades inventing and developing
VelocImmune and related VelociSuite® technologies. Dr. Yancopoulos
and his team have used VelocImmune technology to create a
substantial portion of all original, FDA-approved or authorized
fully human monoclonal antibodies. This includes REGEN-COV®
(casirivimab and imdevimab), Dupixent, Libtayo® (cemiplimab-rwlc),
Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza®
(evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and
odesivimab-ebgn) and Veopoz® (pozelimab-bbfg).
Dupilumab Development ProgramDupilumab is being
jointly developed by Regeneron and Sanofi under a global
collaboration agreement. To date, dupilumab has been studied across
more than 60 clinical trials involving more than 10,000 patients
with various chronic diseases driven in part by type 2
inflammation.
In addition to the currently approved indications, Regeneron and
Sanofi are studying dupilumab in a broad range of diseases driven
in part by type 2 inflammation or other allergic processes in Phase
3 trials, including chronic pruritus of unknown origin and bullous
pemphigoid. These potential uses of dupilumab are currently under
clinical investigation, and the safety and efficacy in these
conditions have not been fully evaluated by any regulatory
authority.
U.S. INDICATIONS
DUPIXENT is a prescription medicine used:
- to treat adults and children 6 months of age and older with
moderate-to-severe eczema (atopic dermatitis or AD) that is not
well controlled with prescription therapies used on the skin
(topical), or who cannot use topical therapies. DUPIXENT can be
used with or without topical corticosteroids. It is not known if
DUPIXENT is safe and effective in children with atopic dermatitis
under 6 months of age.
- with other asthma medicines for the maintenance treatment of
moderate-to-severe eosinophilic or oral steroid dependent asthma in
adults and children 6 years of age and older whose asthma is not
controlled with their current asthma medicines. DUPIXENT helps
prevent severe asthma attacks (exacerbations) and can improve your
breathing. DUPIXENT may also help reduce the amount of oral
corticosteroids you need while preventing severe asthma attacks and
improving your breathing. It is not known if DUPIXENT is safe and
effective in children with asthma under 6 years of age.
- with other medicines for the maintenance treatment of chronic
rhinosinusitis with nasal polyps (CRSwNP) in adults and children 12
years of age and older whose disease is not controlled. It is not
known if DUPIXENT is safe and effective in children with chronic
rhinosinusitis with nasal polyps under 12 years of age.
- to treat adults and children 1 year of age and older with
eosinophilic esophagitis (EoE), who weigh at least 33 pounds (15
kg). It is not known if DUPIXENT is safe and effective in children
with eosinophilic esophagitis under 1 year of age, or who weigh
less than 33 pounds (15 kg).
- to treat adults with prurigo nodularis (PN). It is not known if
DUPIXENT is safe and effective in children with prurigo nodularis
under 18 years of age.
- with other medicines for the maintenance treatment of adults
with inadequately controlled chronic obstructive pulmonary disease
(COPD) and a high number of blood eosinophils (a type of white
blood cell that may contribute to your COPD). DUPIXENT is used to
reduce the number of flare-ups (the worsening of your COPD symptoms
for several days) and can improve your breathing. It is not known
if DUPIXENT is safe and effective in children with chronic
obstructive pulmonary disease under 18 years of age.
DUPIXENT is not used to relieve sudden breathing problems and
will not replace an inhaled rescue medicine.
IMPORTANT SAFETY INFORMATION
Do
not
use if you are allergic to
dupilumab or to any of the ingredients in DUPIXENT®.
Before
using
DUPIXENT,
tell
your
healthcare
provider
about
all
your
medical
conditions,
including
if
you:
- have eye problems.
- have a parasitic (helminth) infection.
- are scheduled to receive any vaccinations. You should not
receive a “live vaccine” right before and during treatment with
DUPIXENT.
- are pregnant or plan to become pregnant. It is not known
whether DUPIXENT will harm your unborn baby.
- A pregnancy registry for women who take DUPIXENT during
pregnancy collects information about the health of you and your
baby. To enroll or get more information call 1-877-311-8972 or go
to https://mothertobaby.org/ongoing-study/dupixent/.
- are breastfeeding or plan to
breastfeed. It is not known whether DUPIXENT passes into your
breast milk.
Tell your healthcare provider about all the medicines you take,
including prescription and over-the-counter medicines, vitamins,
and herbal supplements.
Especially tell your healthcare provider if you
are taking oral, topical, or inhaled corticosteroid medicines; have
asthma and use an asthma medicine; or have atopic dermatitis,
chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis,
prurigo nodularis, or chronic obstructive pulmonary disease and
also have asthma. Do not change or stop your other
medicines, including corticosteroid medicine or other asthma
medicine, without talking to your healthcare provider. This may
cause other symptoms that were controlled by those medicines to
come back.
DUPIXENT
can
cause
serious
side
effects,
including:
-
Allergic
reactions.
DUPIXENT can cause allergic reactions that can sometimes be
severe. Stop using DUPIXENT and tell your healthcare
provider or get emergency help right away if you get any of the
following signs or symptoms: breathing problems or wheezing,
swelling of the face, lips, mouth, tongue or throat, fainting,
dizziness, feeling lightheaded, fast pulse, fever, hives, joint
pain, general ill feeling, itching, skin rash, swollen lymph nodes,
nausea or vomiting, or cramps in your stomach-area.
-
Eye
problems.
Tell your healthcare provider if you have any new or worsening eye
problems, including eye pain or changes in vision, such as blurred
vision. Your healthcare provider may send you to an ophthalmologist
for an exam if needed.
-
Inflammation
of
your
blood
vessels.
Rarely, this can happen in people with asthma who receive DUPIXENT.
This may happen in people who also take a steroid medicine by mouth
that is being stopped or the dose is being lowered. It is not known
whether this is caused by DUPIXENT. Tell your healthcare provider
right away if you have: rash, chest pain, worsening shortness of
breath, a feeling of pins and needles or numbness of your arms or
legs, or persistent fever.
- Joint aches and
pain. Some people who use DUPIXENT have had trouble
walking or moving due to their joint symptoms, and in some cases
needed to be hospitalized. Tell your healthcare provider about any
new or worsening joint symptoms. Your healthcare provider may stop
DUPIXENT if you develop joint symptoms.
The
most
common
side
effects
include:
- Eczema: injection
site reactions, eye and eyelid inflammation, including redness,
swelling, and itching, sometimes with blurred vision, dry eye, cold
sores in your mouth or on your lips, and high count of a certain
white blood cell (eosinophilia).
-
Asthma:
injection site reactions, high count of a certain white blood cell
(eosinophilia), pain in the throat (oropharyngeal pain), and
parasitic (helminth) infections.
-
Chronic
Rhinosinusitis
with
Nasal
Polyps:
injection site reactions, eye and eyelid inflammation, including
redness, swelling, and itching, sometimes with blurred vision, high
count of a certain white blood cell (eosinophilia), gastritis,
joint pain (arthralgia), trouble sleeping (insomnia), and
toothache.
- Eosinophilic
Esophagitis: injection site reactions, upper respiratory
tract infections, cold sores in your mouth or on your lips, and
joint pain (arthralgia).
- Prurigo Nodularis:
eye and eyelid inflammation, including redness, swelling, and
itching, sometimes with blurred vision, herpes virus infections,
common cold symptoms (nasopharyngitis), dizziness, muscle pain, and
diarrhea.
- Chronic Obstructive Pulmonary
Disease: injection site reactions, common cold symptoms
(nasopharyngitis), high count of a certain white blood cell
(eosinophilia), viral infection, back pain, inflammation inside the
nose (rhinitis), diarrhea, gastritis, joint pain (arthralgia),
toothache, headache, and urinary tract infection.
Tell your healthcare provider if you have any side effect that
bothers you or that does not go away. These are not all the
possible side effects of DUPIXENT. Call your doctor for medical
advice about side effects. You are encouraged to report negative
side effects of prescription drugs to the FDA. Visit
www.fda.gov/medwatch, or call 1-800-FDA-1088.
Use DUPIXENT exactly as prescribed by your healthcare provider.
It’s an injection given under the skin (subcutaneous injection).
Your healthcare provider will decide if you or your caregiver can
inject DUPIXENT. Do not try to prepare and
inject DUPIXENT until you or your caregiver have been trained by
your healthcare provider. In children 12 years of age and older,
it’s recommended DUPIXENT be administered by or under supervision
of an adult. In children 6 months to less than 12 years of age,
DUPIXENT should be given by a caregiver.
Please
see
accompanying
full
Prescribing
Information
including
Patient
Information.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company
that invents, develops and commercializes life-transforming
medicines for people with serious diseases. Founded and led by
physician-scientists, our unique ability to repeatedly and
consistently translate science into medicine has led to
numerous approved treatments and product candidates in development,
most of which were homegrown in our laboratories. Our medicines and
pipeline are designed to help patients with eye diseases, allergic
and inflammatory diseases, cancer, cardiovascular and metabolic
diseases, neurological diseases, hematologic conditions,
infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery
and accelerates drug development using our proprietary
technologies, such as VelociSuite®, which produces optimized fully
human antibodies and new classes of bispecific antibodies. We are
shaping the next frontier of medicine with data-powered insights
from the Regeneron Genetics Center® and pioneering genetic medicine
platforms, enabling us to identify innovative targets and
complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow
Regeneron on LinkedIn, Instagram, Facebook or X.
About SanofiWe are an innovative global
healthcare company, driven by one purpose: we chase the miracles of
science to improve people's lives. Our team, across the world, is
dedicated to transforming the practice of medicine by working to
turn the impossible into the possible. We provide potentially
life-changing treatment options and life-saving vaccine protection
to millions of people globally, while putting sustainability and
social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.
Regeneron Forward-Looking Statements and Use of Digital
MediaThis press release includes forward-looking
statements that involve risks and uncertainties relating to future
events and the future performance of Regeneron Pharmaceuticals,
Inc. (“Regeneron” or the “Company”), and actual events or results
may differ materially from these forward-looking statements. Words
such as “anticipate,” “expect,” “intend,” “plan,” “believe,”
“seek,” “estimate,” variations of such words, and similar
expressions are intended to identify such forward-looking
statements, although not all forward-looking statements contain
these identifying words. These statements concern, and these risks
and uncertainties include, among others, the nature, timing, and
possible success and therapeutic applications of products marketed
or otherwise commercialized by Regeneron and/or its collaborators
or licensees (collectively, “Regeneron’s Products”) and product
candidates being developed by Regeneron and/or its collaborators or
licensees (collectively, “Regeneron’s Product Candidates”) and
research and clinical programs now underway or planned, including
without limitation Dupixent® (dupilumab) as an add-on maintenance
treatment of adults with inadequately controlled chronic
obstructive pulmonary disease (“COPD”) and an eosinophilic
phenotype; uncertainty of the utilization, market acceptance, and
commercial success of Regeneron’s Products and Regeneron’s Product
Candidates and the impact of studies (whether conducted by
Regeneron or others and whether mandated or voluntary), including
the studies discussed or referenced in this press release, on any
of the foregoing or any potential regulatory approval of
Regeneron’s Products (such as Dupixent) and Regeneron’s Product
Candidates (such as itepekimab); the likelihood, timing, and scope
of possible regulatory approval and commercial launch of
Regeneron’s Product Candidates and new indications for Regeneron’s
Products, such as Dupixent for the treatment of COPD
in Japan and other jurisdictions as well as Dupixent for
the treatment of chronic pruritus of unknown origin, bullous
pemphigoid, and other potential indications; the ability of
Regeneron’s collaborators, licensees, suppliers, or other third
parties (as applicable) to perform manufacturing, filling,
finishing, packaging, labeling, distribution, and other steps
related to Regeneron’s Products and Regeneron’s Product Candidates;
the ability of Regeneron to manage supply chains for multiple
products and product candidates; safety issues resulting from the
administration of Regeneron’s Products (such as Dupixent) and
Regeneron’s Product Candidates (such as itepekimab) in patients,
including serious complications or side effects in connection with
the use of Regeneron’s Products and Regeneron’s Product Candidates
in clinical trials; determinations by regulatory and administrative
governmental authorities which may delay or restrict Regeneron’s
ability to continue to develop or commercialize Regeneron’s
Products and Regeneron’s Product Candidates; ongoing regulatory
obligations and oversight impacting Regeneron’s Products, research
and clinical programs, and business, including those relating to
patient privacy; the availability and extent of reimbursement of
Regeneron’s Products from third-party payers, including private
payer healthcare and insurance programs, health maintenance
organizations, pharmacy benefit management companies, and
government programs such as Medicare and Medicaid; coverage and
reimbursement determinations by such payers and new policies and
procedures adopted by such payers; competing drugs and product
candidates that may be superior to, or more cost effective than,
Regeneron’s Products and Regeneron’s Product Candidates; the extent
to which the results from the research and development programs
conducted by Regeneron and/or its collaborators or licensees may be
replicated in other studies and/or lead to advancement of product
candidates to clinical trials, therapeutic applications, or
regulatory approval; unanticipated expenses; the costs of
developing, producing, and selling products; the ability of
Regeneron to meet any of its financial projections or guidance and
changes to the assumptions underlying those projections or
guidance; the potential for any license, collaboration, or supply
agreement, including Regeneron’s agreements with Sanofi and Bayer
(or their respective affiliated companies, as applicable) to be
cancelled or terminated; the impact of public health outbreaks,
epidemics, or pandemics (such as the COVID-19 pandemic) on
Regeneron's business; and risks associated with intellectual
property of other parties and pending or future litigation relating
thereto (including without limitation the patent litigation and
other related proceedings relating to EYLEA® (aflibercept)
Injection), other litigation and other proceedings and government
investigations relating to the Company and/or its operations
(including the pending civil proceedings initiated or joined by the
U.S. Department of Justice and the U.S. Attorney's Office for the
District of Massachusetts), the ultimate outcome of any such
proceedings and investigations, and the impact any of the foregoing
may have on Regeneron’s business, prospects, operating results, and
financial condition. A more complete description of these and other
material risks can be found in Regeneron’s filings with the U.S.
Securities and Exchange Commission, including its Form 10-K for the
year ended December 31, 2023 and its Form 10-Q for the quarterly
period ended June 30, 2024. Any forward-looking statements are made
based on management’s current beliefs and judgment, and the reader
is cautioned not to rely on any forward-looking statements made by
Regeneron. Regeneron does not undertake any obligation to update
(publicly or otherwise) any forward-looking statement, including
without limitation any financial projection or guidance, whether as
a result of new information, future events, or
otherwise. Regeneron uses its media and investor relations
website and social media outlets to publish important information
about the Company, including information that may be deemed
material to investors. Financial and other information about
Regeneron is routinely posted and is accessible on Regeneron's
media and investor relations website
(https://investor.regeneron.com) and its LinkedIn page
(https://www.linkedin.com/company/regeneron-pharmaceuticals).
Sanofi Forward-Looking StatementsThis press
release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates regarding
the marketing and other potential of the product, or regarding
potential future revenues from the product. Forward-looking
statements are generally identified by the words “expects”,
“anticipates”, “believes”, “intends”, “estimates”, “plans” and
similar expressions. Although Sanofi’s management believes that the
expectations reflected in such forward-looking statements are
reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and
uncertainties, many of which are difficult to predict and generally
beyond the control of Sanofi, that could cause actual results and
developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, unexpected regulatory actions or delays, or government
regulation generally, that could affect the availability or
commercial potential of the product, the fact that product may not
be commercially successful, the uncertainties inherent in research
and development, including future clinical data and analysis of
existing clinical data relating to the product, including post
marketing, unexpected safety, quality or manufacturing issues,
competition in general, risks associated with intellectual property
and any related future litigation and the ultimate outcome of such
litigation, and volatile economic and market conditions, and the
impact that pandemics or other global crises may have on us, our
customers, suppliers, vendors, and other business partners, and the
financial condition of any one of them, as well as on our employees
and on the global economy as a whole. The risks and uncertainties
also include the uncertainties discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under “Risk Factors” and “Cautionary Statement
Regarding Forward-Looking Statements” in Sanofi’s annual report on
Form 20-F for the year ended December 31, 2023. Other than as
required by applicable law, Sanofi does not undertake any
obligation to update or revise any forward-looking information or
statements.
All trademarks mentioned in this press release are the property
of the Sanofi group apart from VelociSuite and Regeneron Genetics
Center.
Regeneron Contacts: |
|
|
|
Media
RelationsHannah KwaghTel: +1
914-847-6314Hannah.Kwagh@regeneron.com |
Investor RelationsVesna
TosicTel: +1 914-847-5443Vesna.Tosic@regeneron.com |
|
|
Sanofi
Contacts: |
|
|
|
Media
RelationsSandrine GuendoulTel: +33 6 25
09 14 25
Sandrine.Guendoul@sanofi.com Evan
Berland Tel: + 1
215-432-0234Evan.Berland@sanofi.comVictor
Rouault Tel: + 33 6 70 93 71 40
Victor.Rouault@sanofi.com Timothy
Gilbert Tel: +1
516-521-2929Timothy.Gilbert@sanofi.com |
Investor
RelationsThomas Kudsk Larsen Tel: +44
7545 513 693 Thomas.Larsen@sanofi.comAlizé
Kaisserian Tel: + 33 6 47 04 12 11
Alize.Kaisserian@sanofi.comArnaud DelepineTel: +33
6 73 69 36 93Arnaud.Delepine@sanofi.comFelix
LauscherTel: +1
908-612-7239Felix.Lauscher@sanofi.comKeita
BrowneTel: +1
781-249-1766Keita.Browne@sanofi.comNathalie
PhamTel: +33 (0)7 85 93 30
17Nathalie.Pham@sanofi.comTarik ElgoutniTel: +1
617-710-3587Tarik.Elgoutni@sanofi.com
Thibaud Châtelet Tel: +33 6 80 80 89
90 Thibaud.Chatalet@sanofi.com |
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Sanofi (EU:SAN)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024